Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aeolus Pharmaceuticals, Inc. (OTC: AOLS).

Full DD Report for AOLS

You must become a subscriber to view this report.

Recent News from (OTC: AOLS)

Aeolus Announces Commencement of Assignment for the Benefit of Creditors
MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to ...
Date: March, 23 2018 16:30
Pluristem - Hidden Treasures And Sudden Catalysts
Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d...
Source: SeekingAlpha
Date: February, 08 2018 08:18
Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150
- AEOL 10150 Treatment Once Per Day for 60 Days Beginning 24 Hours Post-Exposure Reduced Mortality by 50 Percent - AEOL 10150 Is The Only Drug in Advanced Development by The US Government to Address the Delayed Effects of Radiation - Stockpiled Therapies Such as Neupogen®, Neulasta®...
Date: September, 26 2017 08:00
Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
AEOL 10150 treatment once per day for 60 days beginning 24 hours post-exposure: significantly improved survival at 180 Days delayed onset of lethal effects by 90 days Increased mean survival at 360 days Data presented at the American College of Clinical Pharmac...
Date: September, 22 2017 08:00
Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats
Exposure to the Nerve Agent Surrogate Pilocarpine Causes Prolonged Seizures (Status Epilepticus) that Result in Significant Oxidative Stress Status Epilepticus Induced Oxidative Stress Causes Brain Damage, Cognitive Impairment, and Additional Mortality in Initial Survivors of Nerve A...
Date: September, 20 2017 08:00
AEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects
Single dose well tolerated up to 75 mg No serious adverse events reported No neurological or cardiovascular irregularities reported Analysis and Modeling of PK data suggests: 75 to 125 mg dose for Lung Radiation indication 40 to 50 mg dose for sulfur mustard gas and...
Date: September, 18 2017 08:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AOLS.

About Aeolus Pharmaceuticals, Inc. (OTC: AOLS)

Logo for Aeolus Pharmaceuticals, Inc. (OTC: AOLS)

Aeolus is developing a portfolio of novel metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL , is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. The Company is also developing AEOL as a treatment for Parkinson s disease and AEOL as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti viral therapies. For more information, please visit Aeolus s corporate website at


Contact Information



Current Management

  • David Charles Cavalier / CFO, COO, IR
  • John L. McManus / CEO
  • David Charles Cavalier / Chairman
  • John Clerici /
  • John Farah /
  • Mitchell Kaye /
  • Amit Kumar /
  • Chris Rallis /
  • Jeffrey Scott /

Current Share Structure

  • Market Cap: $4,562,575 - 03/16/2018
  • Authorized: 200,000,000 - 09/30/2016
  • Issue and Outstanding: 152,085,825 - 02/17/2017
  • Float: 53,784,744 - 05/16/2016


Recent Filings from (OTC: AOLS)



Daily Technical Chart for (OTC: AOLS)

Daily Technical Chart for (OTC: AOLS)

Stay tuned for daily updates and more on (OTC: AOLS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AOLS)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AOLS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AOLS and does not buy, sell, or trade any shares of AOLS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: